We herein show first time evidence that dual HER2 blockade by trastuzumab/pertuzumab is associated with a marked inhibition of HER2 receptor expression on plasma membrane of cancer cells in vitro and in vivo, which limits the targetable HER2 receptor available to T-DM1. Here, ERBB2 is linked to cancer.